Guest Editor(s)

• Shu-Kui Qin, MD, PhD

  Deputy Director of People's Liberation Army (PLA) 81 Hospital, Nanjing, China.
  Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital;Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of Chinese Society of Clinical Oncology (CSCO).

  E-mail

Special Issue Introduction

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally due, in part, to the majority of patients diagnosed with intermediate or advanced stage disease. Our increased understanding of the heterogeneous molecular pathogenesis of HCC has led to significant developments in novel targeted therapies. Despite these advances, there remains a high unmet need for new treatment options.

Participants

1. Xin-Rong Yang Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
2. Philippe Merle INSERM, U1052 UMR CNRS 5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
3. Massimo Colombo Humanitas Clin & Res Ctr IRCCS, Ctr Translat Res Hepatol, MI, Italy.
The list is arranged in no particular order and to be updated.

Submission Deadline

30 May 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/HR/?IssueId=328
Submission Deadline: 30 May 2020
Contacts: Haidi Ding, Assistant Editor, editor_Haidi@hrjournal.net